Biohaven Ltd. (BHVN) Price & Analysis

Compare

735 Followers

BHVN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.79 - $55.70

Previous CloseN/A

Volume146.24K

Average Volume (3M)2.04M

Market Cap

$1.56B

Enterprise Value$1.33B

Total Cash (Recent Filing)$404.98M

Total Debt (Recent Filing)$286.87M

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Nov 18, 2025

EPS Estimate

-1.88

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.94

Shares Outstanding105,791,000

10 Day Avg. Volume2,180,162

30 Day Avg. Volume2,035,651

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.86

Enterprise Value/Revenue346.93

Enterprise Value/Gross Profit-13.72K

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$42.85

Price Target Upside191.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Investor ConfidenceShares of Biohaven increased as much as 9.5% during trading hours, indicating investor optimism.

Market PotentialThere are currently no FDA-approved therapies for spinocerebellar ataxia (SCA), which suggests a significant market opportunity for troriluzole upon approval.

Regulatory ApprovalTroriluzole is under FDA priority review for the treatment of spinocerebellar ataxia with a PDUFA in 4Q25, and it is more likely than not to receive FDA approval.

Bears Say

Clinical Trial ResultsThe Phase III trial missed the primary f-SARA endpoint after 1 year of placebo-controlled dosing.

Financial RisksFinancing overhang remains a near-term risk, with the potential need for additional financing to support a launch and continued pipeline development.

Operational ChallengesTroriluzole failed in OCD, which is disappointing and may also be pressuring the stock.

Biohaven Ltd. News

Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2d ago

Biohaven initiated with a Buy at Citi

Citi analyst Samantha Semenkow initiated coverage of Biohaven (BHVN) with a Buy rating and $28 price target The...

2d ago

BHVN

Biohaven price target lowered to $26 from $27 at UBS

UBS lowered the firm’s price target on Biohaven (BHVN) to $26 from $27 and keeps a Buy rating...

3d ago

BHVN

RBC lists biotech winners should RFK depart HHS

RBC Capital explores the implications on biotech stocks of Robert F. Kennedy Jr. potentially departing the Health and...

8d ago

ALKS

AXSM

RBC lists biotech winners should RFK departure HHS

RBC Capital explores the implications on biotech stocks of Robert F. Kennedy Jr. potentially departing the Health and...

8d ago

ALKS

AXSM

Biohaven initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Biohaven (BHVN) with a Strong Buy rating and $75 price target Shares, down...

16d ago

BHVN

BHVN Lawsuit Alert! Class Action Lawsuit Against Biohaven Ltd.

A class action lawsuit was filed against Biohaven Ltd. ($BHVN) by Levi & Korsinsky on July 14, 2025. The plaintiffs (shareholders)...

22d ago

BHVN

3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

25d ago

BHVN

CLDX

Optimistic Buy Rating for Biohaven Ltd. Driven by Regulatory Progress and Market Potential of Troriluzole

William Blair analyst Myles Minter has maintained their bullish stance on BHVN stock, giving a Buy rating on...

27d ago

BHVN

Biohaven Ltd. Awaits FDA Decision on Troriluzole

The latest announcement is out from Biohaven Ltd. ( ($BHVN) ). Biohaven Ltd. announced an update on its...

28d ago

BHVN

RBC says PTC Therapeutics CRL may signal difficulty for Biohaven

RBC Capital analyst Leonid Timashev notes that PTC Therapeutics (PTCT) received a complete response letter for vatiquinone in...

1M ago

BHVN

PTCT

Biohaven price target raised to $60 from $59 at BTIG

BTIG analyst Thomas Shrader raised the firm’s price target on Biohaven (BHVN) to $60 from $59 and keeps...

1M ago

BHVN

Biohaven Ltd. Reports Q2 2025 Financial Results

Biohaven Ltd. ( ($BHVN) ) has released its Q2 earnings. Here is a breakdown of the information Biohaven...

1M ago

BHVN

Biohaven Ltd. Files Prospectus for Share Resale

The latest update is out from Biohaven Ltd. ( ($BHVN) ). On August 15, 2025, Biohaven Ltd. filed...

1M ago

BHVN

BHVN FAQ

What was Biohaven Ltd.’s price range in the past 12 months?

Biohaven Ltd. lowest stock price was $12.79 and its highest was $55.70 in the past 12 months.

What is Biohaven Ltd.’s market cap?

Biohaven Ltd.’s market cap is $1.56B.

When is Biohaven Ltd.’s upcoming earnings report date?

Biohaven Ltd.’s upcoming earnings report date is Nov 18, 2025 which is in 60 days.

How were Biohaven Ltd.’s earnings last quarter?

Biohaven Ltd. released its earnings results on Aug 11, 2025. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of -$1.902 by -$0.038.

Is Biohaven Ltd. overvalued?

According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biohaven Ltd. pay dividends?

Biohaven Ltd. does not currently pay dividends.

What is Biohaven Ltd.’s EPS estimate?

Biohaven Ltd.’s EPS estimate is -1.88.

How many shares outstanding does Biohaven Ltd. have?

Biohaven Ltd. has 105,791,000 shares outstanding.

What happened to Biohaven Ltd.’s price movement after its last earnings report?

Biohaven Ltd. reported an EPS of -$1.94 in its last earnings report, missing expectations of -$1.902. Following the earnings report the stock price went down -9.023%.

Which hedge fund is a major shareholder of Biohaven Ltd.?

Currently, no hedge funds are holding shares in BHVN

Biohaven Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-295.94%

Trailing 12-Months

Asset Growth

-5.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biohaven Ltd.

Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.

Biohaven Ltd. (BHVN) Earnings & Revenues

Historic Earnings Reports

BHVN Stock 12 Month Forecast

Average Price Target

$42.85

▲(191.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","28":"$28","44":"$44","60":"$60","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,28,44,60,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.89,20.43692307692308,24.983846153846155,29.53076923076923,34.07769230769231,38.62461538461539,43.17153846153846,47.71846153846154,52.26538461538462,56.8123076923077,61.35923076923078,65.90615384615384,70.45307692307694,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.89,17.963846153846156,20.03769230769231,22.111538461538462,24.185384615384617,26.259230769230772,28.333076923076923,30.40692307692308,32.48076923076923,34.55461538461539,36.62846153846154,38.7023076923077,40.776153846153846,{"y":42.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.89,16.12923076923077,16.36846153846154,16.607692307692307,16.846923076923076,17.086153846153845,17.325384615384614,17.564615384615387,17.803846153846155,18.043076923076924,18.282307692307693,18.521538461538462,18.76076923076923,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >